Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;20(8):e2304082.
doi: 10.1002/smll.202304082. Epub 2023 Sep 28.

A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts

Affiliations

A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts

Zixin Wang et al. Small. 2024 Feb.

Abstract

Bioenergetic deficits are known to be significant contributors to neurodegenerative diseases. Nevertheless, identifying safe and effective means to address intracellular bioenergetic deficits remains a significant challenge. This work provides mechanistic insights into the energy metabolism-regulating function of colloidal Au nanocrystals, referred to as CNM-Au8, that are synthesized electrochemically in the absence of surface-capping organic ligands. When neurons are subjected to excitotoxic stressors or toxic peptides, treatment of neurons with CNM-Au8 results in dose-dependent neuronal survival and neurite network preservation across multiple neuronal subtypes. CNM-Au8 efficiently catalyzes the conversion of an energetic cofactor, nicotinamide adenine dinucleotide hydride (NADH), into its oxidized counterpart (NAD+ ), which promotes bioenergy production by regulating the intracellular level of adenosine triphosphate. Detailed kinetic measurements reveal that CNM-Au8-catalyzed NADH oxidation obeys Michaelis-Menten kinetics and exhibits pH-dependent kinetic profiles. Photoexcited charge carriers and photothermal effect, which result from optical excitations and decay of the plasmonic electron oscillations or the interband electronic transitions in CNM-Au8, are further harnessed as unique leverages to modulate reaction kinetics. As exemplified by this work, Au nanocrystals with deliberately tailored structures and surfactant-free clean surfaces hold great promise for developing next-generation therapeutic agents for neurodegenerative diseases.

Keywords: bioenergy metabolism; catalytic therapeutics; gold nanocrystals; nanozymes; neurodegenerative diseases; neuroprotection.

PubMed Disclaimer

Similar articles

Cited by

  • The Evolving Use of Gold Nanoparticles as a Possible Reversal Agent for the Symptoms of Neurodegenerative Diseases: A Narrative Review.
    Kaye AD, Sala KR, Dethloff D, Norton M, Moss C, Plessala MJ, Derouen AG, Lopez Torres Y, Kim J, Tirumala S, Shekoohi S, Varrassi G. Kaye AD, et al. Cureus. 2024 Jul 18;16(7):e64846. doi: 10.7759/cureus.64846. eCollection 2024 Jul. Cureus. 2024. PMID: 39156432 Free PMC article. Review.
  • Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
    Vucic S, Menon P, Huynh W, Mahoney C, Ho KS, Hartford A, Rynders A, Evan J, Evan J, Ligozio S, Glanzman R, Hotchkin MT, Kiernan MC. Vucic S, et al. EClinicalMedicine. 2023 Jun 8;60:102036. doi: 10.1016/j.eclinm.2023.102036. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396808 Free PMC article.
  • Protein Corona Composition of Gold Nanocatalysts.
    Ashkarran AA, Tadjiki S, Lin Z, Hilsen K, Ghazali N, Krikor S, Sharifi S, Asgari M, Hotchkin M, Dorfman A, Ho KS, Mahmoudi M. Ashkarran AA, et al. ACS Pharmacol Transl Sci. 2024 Mar 14;7(4):1169-1177. doi: 10.1021/acsptsci.4c00028. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633595 Free PMC article.
  • CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
    Writing Committee for the HEALEY ALS Platform Trial; Berry JD, Maragakis NJ, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Stommel EW, Chase M, Pothier L, Harkey BA, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Babu S, Andrews J, D'Agostino D, Tustison E, Scirocco E, Giacomelli E, Alameda G, Locatelli E, Ho D, Quick A, Ajroud-Driss S, Katz J, Heitzman D, Appel SH, Shroff S, Felice KJ, Simmons Z, Miller T, Olney N, Weiss MD, Goutman SA, Fernandes JA Jr, Jawdat O, Owegi MA, Foster L, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson C, Ladha S, Heiman-Patterson T, Caress J, Swenson A, Peltier A, Lewis R, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff CE, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Glass J, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Rynders A, Evan J, Evan J, Hartford A, Sepassi M, Ho KS, Glanzman R, Greenberg B, Hotchkin MT, Paganoni S, Cudkowicz ME; HEALEY ALS Platform Trial Study Group. Writing Committee for the HEALEY ALS Platform Trial, et al. JAMA. 2025 Feb 17;333(13):1138-49. doi: 10.1001/jama.2024.27643. Online ahead of print. JAMA. 2025. PMID: 40067821 Free PMC article.
  • Blueprint of Collapse: Precision Biomarkers, Molecular Cascades, and the Engineered Decline of Fast-Progressing ALS.
    Șerban M, Toader C, Covache-Busuioc RA. Șerban M, et al. Int J Mol Sci. 2025 Aug 21;26(16):8072. doi: 10.3390/ijms26168072. Int J Mol Sci. 2025. PMID: 40869392 Free PMC article. Review.

References

    1. S. Camandola, M. P. Mattson, EMBO J. 2017, 36, 1474.
    1. H. Fu, J. Hardy, K. E. Duff, Nat. Neurosci. 2018, 21, 1350.
    1. M. Mamelak, Neurosci. Biobehav. Rev. 2017, 75, 297.
    1. Y. J. Hou, S. Lautrup, S. Cordonnier, Y. Wang, D. L. Croteau, E. Zavala, Y. Q. Zhang, K. Moritoh, J. F. O'Connell, B. A. Baptiste, T. V. Stevnsner, M. P. Mattson, V. A. Bohr, Proc. Natl. Acad. Sci. U. S. A. 2018, 115, E1876.
    1. A. N. Long, K. Owens, A. E. Schlappal, T. Kristian, P. S. Fishman, R. A. Schuh, BMC Neurol. 2015, 15, 19.

Publication types

LinkOut - more resources